Acura Pharmaceuticals, Inc. Stock Price - ACUR

Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN
Acura Pharmaceuticals, Inc. ACUR Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.00% 0.1414 0.00 0.00 0.00 0.1414 10:27:22
Bid Price Ask Price Spread Spread % News
0.1415 0.2196 0.0782 35.61% - -
Stock Trades Traded Volume Average Volume 52 Week Range
2 15 4,073 0.0601 - 0.48
Last Trade Time Type Quantity Stock Price Currency
09:34:30 5 $ 0.1414 USD

Acura Pharmaceuticals, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 3.01M 21.3M $ -5.68M - -0.53 7.39M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Acura Pharmaceuticals, Inc. News

Latest ACUR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ACUR Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.19750.210.13010.15856008k3k-0.0561-28.41%
1 Month0.14220.2790.13010.186160018k5k-0.0008-0.56%
3 Months0.180.2830.13010.225412068k5k-0.0386-21.44%
6 Months0.06010.290.06010.189612068k7k0.0813135.27%
1 Year0.40.480.06010.20551140k11k-0.2586-64.65%
3 Years0.550.87020.06010.42891235k16k-0.4086-74.29%
5 Years0.550.87020.06010.42891235k16k-0.4086-74.29%

Acura Pharmaceuticals, Inc. Description

We are a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion and Limitx Technologies are intended to address methods of product tampering associated with opioid abuse with opioid abuse while our Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine into methamphetamine. Our Limitx Technology, is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. We have completed two clinical studies of our lead Limitx immediate release oral abuse deterrent drug candidate using the opioid hydromorphone HCI. (LTX-04). The Company has changed its development focus to LTX-03, an immediate-release hydrocodone bitartrate product, which is more likely to be abused by excess oral consumption. Our Aversion Technology incorporates gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Our Impede Technology is a proprietary mixture of inactive ingredients that prevents the extraction of pseudoephedrine, or PSE, from tablets using known extraction methods and disrupts the direct conversion of PSE from tablets into methamphetamine.


Your Recent History
USOTC
ACUR
Acura Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.